Plasma plasminogen activator inhibitor-1 levels and nonalcoholic fatty liver in individuals with features of metabolic syndrome.
Fatty liver represents the liver component of metabolic syndrome and may be involved in plasminogen activator inhibitor-1 (PAI-1) synthesis. We studied plasma PAI-1 levels and relationships with risk factors for metabolic syndrome, including fatty liver, in 170 patients. Liver ultrasound scan was performed on all patients, and a liver biopsy was performed on those patients with chronically elevated transaminase levels. Plasma PAI-1 levels correlated significantly (P < .05) with body mass index, degree of steatosis, insulin resistance, insulin level, waist circumference, triglycerides, and high-density lipoprotein (HDL) -cholesterol. However, only body mass index (beta = .455) and HDL-cholesterol (beta = .293) remained predictors of PAI-1 levels. Liver biopsy revealed a significant correlation (P < .05) between insulin resistance (r = 0.381) or insulin level (r = 0.519) and liver fibrosis. In patients presenting features of metabolic syndrome, plasma PAI-1 levels were mainly conditioned by the whole-body fat content.
de Larrañaga
Gabriela
G
Hemostasis and Thrombosis Laboratory, Hospital of Infectious diseases, F J Muniz, Argentina. gabriela@inkmedia.com.ar
Wingeyer
Silvia Perés
SP
Graffigna
Mabel
M
Belli
Susana
S
Bendezú
Karla
K
Alvarez
Silvia
S
Levalle
Oscar
O
Fainboim
Hugo
H
D050154:Adiposity; D000328:Adult; D015992:Body Mass Index; D005234:Fatty Liver / Q000097:blood* / Q000150:complications / Q000473:pathology; D005260:Female; D006801:Humans; D007328:Insulin / Q000097:blood; D007333:Insulin Resistance; D008297:Male; D024821:Metabolic Syndrome / Q000097:blood* / Q000209:etiology / Q000473:pathology; D008875:Middle Aged; D009765:Obesity / Q000097:blood / Q000150:complications / Q000473:pathology; D017395:Plasminogen Activator Inhibitor 1 / Q000097:blood*; D012307:Risk Factors
D007328:Insulin; D017395:Plasminogen Activator Inhibitor 1; C051321:SERPINE1 protein, human